BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26130958)

  • 1. Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics.
    Kim EA; Kim YH; Kang HW; Yoon HY; Kim WT; Kim YJ; Yun SJ; Moon SK; Choi YH; Kim IY; Lee SC; Kim WJ
    J Korean Med Sci; 2015 Jul; 30(7):937-42. PubMed ID: 26130958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-139-5p is Increased in the Peripheral Blood of Patients with Prostate Cancer.
    Pang C; Liu M; Fang W; Guo J; Zhang Z; Wu P; Zhang Y; Wang J
    Cell Physiol Biochem; 2016; 39(3):1111-7. PubMed ID: 27562849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.
    Chen M; Ma T; Li J; Zhang HJ; Li Q; Wang JJ; Sang T; Cao CL; Cui XW
    Med Sci Monit; 2021 Feb; 27():e929913. PubMed ID: 33556045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additional value of the ratio of serum total testosterone to total prostate-specific antigen in the diagnosis of prostate cancer in a Chinese population.
    Xu L; Hu X; Zhu Y; Lu J; Xu Y; Wang G; Guo J
    Andrologia; 2018 Mar; 50(2):. PubMed ID: 28752596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.
    Zhang YX; Wang L; Ji PY; Zhao GG; Zhong GP; Wang ZP
    Arch Med Res; 2013 May; 44(4):259-65. PubMed ID: 23707648
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Kim YH; Byun YJ; Kim WT; Jeong P; Yan C; Kang HW; Kim YJ; Lee SC; Moon SK; Choi YH; Yun SJ; Kim WJ
    J Korean Med Sci; 2018 Nov; 33(47):e303. PubMed ID: 30450027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
    Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
    IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.
    Mao Y; Li K; Lu L; Si-Tu J; Lu M; Gao X
    Cancer Biomark; 2016; 16(3):351-8. PubMed ID: 26889981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of kallikrein-related peptidase 7 is decreased in prostate cancer.
    Zhang CY; Zhu Y; Rui WB; Dai J; Shen ZJ
    Asian J Androl; 2015; 17(1):106-10. PubMed ID: 25219913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinesin Family Member 11 mRNA Expression Predicts Prostate Cancer Aggressiveness.
    Piao XM; Byun YJ; Jeong P; Ha YS; Yoo ES; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2017 Aug; 15(4):450-454. PubMed ID: 27842896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
    Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
    PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MMP26: A potential biomarker for prostate cancer.
    Cheng T; Li F; Wei R; Lv MQ; Zhou Y; Dai Y; Yuan Y; Jiang GY; Ma D; Gao QL
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):891-894. PubMed ID: 29270749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Differential Patterns of Oxidative Biomarkers in Prostate Cancer Progression.
    Wu T; Kasper S; Wong RM; Bracken B
    Clin Genitourin Cancer; 2020 Apr; 18(2):e174-e179. PubMed ID: 31899150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
    Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
    J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
    Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
    Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel non-invasive biological marker to overcome the shortcomings of PSA in diagnosis and risk stratification for prostate cancer: Initial prospective study of developmental endothelial locus-1 protein.
    Chung JW; Kim HT; Ha YS; Lee EH; Chun SY; Lee CH; Byeon KH; Choi SH; Lee JN; Kim BS; Kim TH; Yoo ES; Yoon GS; Baek MC; Kwon TG
    PLoS One; 2021; 16(4):e0250254. PubMed ID: 33901217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.
    Kiebish MA; Tekumalla P; Ravipaty S; Dobi A; Srivastava S; Wu W; Patil S; Friss T; Klotz A; Srinivasan A; Cullen J; Rosner IL; Ali A; Laszlo S; Petrovic M; Fleshner N; Garren J; Miller G; Mahaveer Chand N; Rodrigues LO; Granger E; Kellogg MD; Luan S; Diamandis E; Akmaev VR; Sarangarajan R; Bountra C; Freedland SJ; McLeod DG; Narain NR
    Sci Rep; 2021 Jul; 11(1):15052. PubMed ID: 34302010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using "Light-Cycler"-based quantitative real-time polymerase chain reaction.
    Straub B; Müller M; Krause H; Schrader M; Goessl C; Heicappell R; Miller K
    Urology; 2001 Nov; 58(5):815-20. PubMed ID: 11711374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.